

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CLARITY MEDICAL GROUP HOLDING LIMITED

清晰醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1406)

- (1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF AUDIT COMMITTEE;**
- (2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR;**
- (3) CHANGE OF AUTHORISED REPRESENTATIVE; AND**
- (4) RE-COMPLIANCE WITH THE LISTING RULES**

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF AUDIT COMMITTEE

The board (the “**Board**”) of directors (the “**Directors**”) of Clarity Medical Group Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Dr. Chen Poujian (“**Dr. Chen**”) has been appointed as an independent non-executive Director (“**INED**”) and a member of the audit committee of the Company (the “**Audit Committee**”) by the Board, with effect from 11 November 2025.

Dr. Chen will enter into a letter of appointment with the Company for a term of three years commencing from the date of appointment, which may be terminated by not less than three calendar months’ notice in writing or payment in lieu of notice served by either party on the other. Dr. Chen is entitled to receive a fixed director’s remuneration of HK\$300,000 per annum, which was recommended by the remuneration committee of the Company (the “**Remuneration Committee**”) and determined by the Board, with reference to his responsibilities, experience and market rate of directors’ remuneration of companies listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) that are of a comparable size and operation as the Company.

The biographical details of Dr. Chen required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) are set out below:

Dr. Chen, aged 60, has been serving as the chairman and executive director of Ruihua Health Assurance Corporation (瑞華健康保險股份有限公司) since July 2018. He possesses over 35 years of experience in insurance and investment.

Dr. Chen is a senior economist with a PhD degree in Economics from Zhongnan University of Economics and Law. He obtained a bachelor's degree from Central University of Finance and Economics in 1986 and a master's degree from Zhongnan University of Economics and Law in 1992.

In 1988, Dr. Chen joined Ping An Insurance (Group) Company of China, Ltd. as a founding team member, serving as general manager of reinsurance division in the Jiangsu branch. He founded Tianan Insurance Co., Ltd (天安保險股份有限公司) in 1994 and John Hancock Tianan Life Insurance Company in 2001. From October 1994 to March 2010, he served as CEO and chairman of Tianan Insurance Co., Ltd. In 2012, Dr. Chen founded China Horae Capital Management (中國紅瑞資本管理集團有限公司), where he served as CEO. In 2016, Dr. Chen spearheaded the establishment of Ruihua Health Assurance Corporation and, upon its official approval to commence business by the regulator in 2018, was appointed chairman.

To the best of the Directors' information, knowledge and belief, having made all reasonable enquiries, save as disclosed above, Dr. Chen (i) did not hold any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years; (ii) does not have any other major appointments and professional qualifications; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder (as defined under the Listing Rules) of the Company.

As at the date of this announcement, Dr. Chen (i) does not have, and is not deemed to have any interests or short positions in any shares or underlying shares and debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (ii) does not have any other positions held within the Company or other members of the Group.

Save as disclosed above, as far as the Board is aware, there is no other information that needs to be disclosed in accordance with Rule 13.51(2) of the Listing Rules concerning the appointment of Dr. Chen, and there are no other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

Dr. Chen has confirmed that he has met the independence criteria set out in Rule 3.13 of the Listing Rules.

The Board would like to extend a warm welcome to Dr. Chen on joining the Board.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that Professor Wang Qinmei ("**Prof. Wang**") has been appointed as a non-executive Director ("**NED**") by the Board, with effect from 11 November 2025.

Prof. Wang will enter into a letter of appointment with the Company for a term of three years commencing from the date of appointment, which may be terminated by not less than three calendar months' notice in writing or payment in lieu of notice served by either party on the other. Prof. Wang is entitled to receive a fixed director's remuneration of HK\$300,000 per annum, which was recommended by the Remuneration Committee and determined by the Board, with reference to his responsibilities, experience and market rate of directors' remuneration of companies listed on the Stock Exchange that are of a comparable size and operation as the Company.

The biographical details of Prof. Wang required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules are set out below:

Prof. Wang, aged 70, is currently the professor of ophthalmology and optometry, chief physician, doctoral supervisor at Wenzhou Medical University. He is currently the deputy president and chief medical officer of Wenzhou Medical University Eye and Vision Hospital Group (溫州醫科大學眼視光醫院集團). He possesses over 40 years of experience in ophthalmology.

After graduation, Prof. Wang joined Wenzhou Medical University Affiliated Eye and Vision Hospital (溫州醫學院附屬眼視光醫院), where he served as the executive president. He was also an expert member, member of the Corneal Disease Group and former deputy leader of Corneal Disease Group of the ophthalmology branch of the Chinese Medical Association (中華醫學會眼科學分會).

He served as the chief editor of multiple textbooks including Refractive Surgery for the Ministry of Education's 10th, 12th, and 13th Five-Year Plans and as lead translator and contributing translator for several monographs in refractive surgery.

Besides, He was elected as a member of the 10th Central Committee of the China Democratic League in 2008.

To the best of the Directors' information, knowledge and belief, having made all reasonable enquiries, save as disclosed above, Prof. Wang (i) did not hold any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years; (ii) does not have any other major appointments and professional qualifications; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder (as defined under the Listing Rules) of the Company.

As at the date of this announcement, Prof. Wang (i) does not have, and is not deemed to have any interests or short positions in any shares or underlying shares and debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (ii) does not have any other positions held within the Company or other members of the Group.

Save as disclosed above, as far as the Board is aware, there is no other information that needs to be disclosed in accordance with Rule 13.51(2) of the Listing Rules concerning the appointment of Prof. Wang, and there are no other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to extend a warm welcome to Prof. Wang on joining the Board.

CHANGE OF AUTHORISED REPRESENTATIVE

The Board announces that with effect from 11 November 2025, (i) Mr. Hui Yung Chris ceased to act as the authorised representative of the Company under the Rule 3.05 of the Listing Rules (the “**Authorised Representative**”); and (ii) Mr. Jiang Bo, the executive Director and chief executive officer of the Company, has been appointed to act as the Authorised Representative.

The Board would like to extend its warm welcome to Mr. Jiang Bo in relation to his new roles as the Authorised Representative.

RE-COMPLIANCE WITH THE LISTING RULES

Reference is made to the announcement of the Company dated 1 September 2025 in relation to the non-compliance of Rule 3.21 of the Listing Rules. Following the appointment of Dr. Chen as an independent non-executive Director and a member of the Audit Committee, the Company has re-complied with the requirements of Rule 3.21 of the Listing Rules.

By order of the Board
CLARITY MEDICAL GROUP HOLDING LIMITED
WU Ting Yuk Anthony
Non-Executive Director and Chairman

Hong Kong, 11 November 2025

As at the date of this announcement, the Board comprises Mr. JIANG Bo and Mr. HUI Yung Chris as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director, Mr. CHEN Jiarong and Prof. WANG Qinmei as non-executive Directors, and Ms. CHENG Jessica, Mr. WANG Can, Ms. CI Ying and Dr. CHEN Poujian as independent non-executive Directors.